Ignite Creation Date:
2025-12-24 @ 4:38 PM
Ignite Modification Date:
2026-02-10 @ 10:43 AM
Study NCT ID:
NCT02595866
Status:
COMPLETED
Last Update Posted:
2024-08-09
First Post:
2015-11-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | AIDS-Related Non-Hodgkin Lymphoma | View |
| None | Clinical Stage III Cutaneous Melanoma AJCC v8 | View |
| None | Clinical Stage IV Cutaneous Melanoma AJCC v8 | View |
| None | Hepatocellular Carcinoma | View |
| None | HIV Infection | View |
| None | Kaposi Sarcoma | View |
| None | Locally Advanced Lung Non-Small Cell Carcinoma | View |
| None | Locally Advanced Malignant Solid Neoplasm | View |
| None | Metastatic Lung Non-Small Cell Carcinoma | View |
| None | Metastatic Malignant Solid Neoplasm | View |
| None | Metastatic Melanoma | View |
| None | Non-Hodgkin Lymphoma | View |
| None | Recurrent Classic Hodgkin Lymphoma | View |
| None | Recurrent Malignant Neoplasm | View |
| None | Refractory Classic Hodgkin Lymphoma | View |
| None | Refractory Malignant Neoplasm | View |
| None | Stage III Lung Cancer AJCC v8 | View |
| None | Stage IV Lung Cancer AJCC v8 | View |
| None | Unresectable Melanoma | View |
Keywords: